Analysts Set Benitec Biopharma Inc. (NASDAQ:BNTC) PT at $22.60

Shares of Benitec Biopharma Inc. (NASDAQ:BNTC) have been assigned a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $22.60.

BNTC has been the topic of a number of recent research reports. JMP Securities upped their price objective on shares of Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a report on Monday, October 14th. Oppenheimer assumed coverage on Benitec Biopharma in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $35.00 price target on the stock. Piper Sandler reiterated an “overweight” rating on shares of Benitec Biopharma in a research note on Friday, October 18th. Leerink Partnrs raised shares of Benitec Biopharma to a “strong-buy” rating in a research report on Monday, July 22nd. Finally, Leerink Partners began coverage on shares of Benitec Biopharma in a research note on Monday, July 22nd. They issued an “outperform” rating and a $13.00 target price on the stock.

Institutional Trading of Benitec Biopharma

A number of institutional investors have recently made changes to their positions in BNTC. GAMMA Investing LLC raised its holdings in shares of Benitec Biopharma by 53.0% during the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,884 shares during the last quarter. Acuta Capital Partners LLC bought a new stake in Benitec Biopharma in the 3rd quarter worth approximately $274,000. Simplify Asset Management Inc. purchased a new stake in Benitec Biopharma during the 2nd quarter valued at $358,000. Geode Capital Management LLC lifted its holdings in shares of Benitec Biopharma by 31.3% during the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock valued at $772,000 after buying an additional 20,012 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in shares of Benitec Biopharma by 35.5% in the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock worth $1,266,000 after buying an additional 64,092 shares during the last quarter. Hedge funds and other institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Stock Up 2.7 %

NASDAQ:BNTC opened at $10.68 on Friday. The firm’s 50-day moving average price is $9.91 and its 200-day moving average price is $9.05. Benitec Biopharma has a 1-year low of $2.69 and a 1-year high of $12.89.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.